- The Union Cabinet chaired by the Prime Minister Shri Narendra Modi today has given its approval for signing of a Memorandum of Understanding (MoU) between India and Nepal on Drug Demand Reduction and Prevention of Illicit Trafficking in Narcotic Drugs and Psychotropic Substances and precursor chemicals and related matters.
- The MoU lists out the areas of cooperation on drug matters between the two countries. It also indicates the mechanism of information exchange and the competent authorities in the two countries who are responsible for the implementation of the MoU and exchange of any information.
- Cooperation on drug matters is expected to curb the illicit traffic of narcotic drugs, psychotropic substances and precursor chemicals in the two countries.
The MoU provides that the Parties shall endeavour to: –
(i) develop mutual cooperation with a view to effectively resolving the issue of illicit traffic in narcotic drugs, psychotropic substances and their precursors, cooperate in drug demand reduction through prevention, awareness, education and community based programmes, treatment and rehabilitation; and
(ii) exchange information of operational, technical and general nature in drug matters, exchange literature on their existing laws, rules, procedures, best practices and methods of curbing illicit trafficking in narcotic drugs, psychotropic substances and their precursors and any further amendments to the existing legislation.
- India has always supported global efforts to counter drug trafficking and is party to several multilateral and bilateral initiatives in this regard as also United Nations (UN) led initiatives.
- In accordance with the spirit of UN Conventions on Narcotic Drugs, effort is made to enter into Bilateral Agreements/MoUs with neighbouring countries and the countries which have a direct bearing on the drug situation prevailing in our country. Such Bilateral Agreements/ MoUs have already been executed with various countries.
- The proposed MoU with Nepal is another such MoU which shall be entered for the purpose of bilateral cooperation on drug matters.